Overview

Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy

Status:
Unknown status
Trial end date:
2020-02-28
Target enrollment:
Participant gender:
Summary
To explore efficacy and safety of 0.5 mg conbercept ophthalmic injection for long-term treatment of polypoid choroidal vasculopathy (PCV) subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Chengdu Kanghong Biotech Co., Ltd.
Chengdu Kanghong Biotech Co.,Ltd.